SCHEMBL7181279

SCHEMBL7181279

Cc1cccc(Cl)c1C(=O)Pc1ccc(OCCC(C)C)cc1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
S1PR1 P21453 1/20 0.44
S1PR5 Q9H228 1/20 0.44
EPHX2 P34913 1/20 0.42
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
ALOX12 P18054 1/20 0.39
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
ALOX5 P09917 1/20 0.37
ITGB1 P05556 2/20 0.36
ITGA5 P08648 2/20 0.36
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175815 0.94 MAPK1 (0.49) MAPK1S1PR1S1PR5EPHX2TP53
SCHEMBL7183087 0.92 MAPK1 (0.49) MAPK1S1PR1S1PR5EPHX2TP53
SCHEMBL7187939 0.88 NR1H4 (0.37) TP53SMN1; SMN2NR1H4ALOX12GAA
SCHEMBL7181306 0.88 MAPK1 (0.43) MAPK1S1PR1S1PR5EPHX2TP53
SCHEMBL7183228 0.87 FAAH (0.41) S1PR1S1PR5TP53SMN1; SMN2ALOX5
SCHEMBL7181143 0.87 MAPT (0.42) MAPK1TP53ALDH1A1KMT2A
SCHEMBL7179827 0.86 TDP1 (0.38) TDP1ITGB1ITGA5THRBITGB3
SCHEMBL7177558 0.86 S1PR1 (0.39) MAPK1S1PR1S1PR5EPHX2TP53
SCHEMBL7183725 0.85 NR5A1 (0.43) S1PR1S1PR5TP53TSHR
SCHEMBL7189820 0.84 MAPT (0.41) SMN1; SMN2GAAHTTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPK1 1801/4885S1PR1 549/4885S1PR5 716/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPK1 2710/4885S1PR1 703/4885S1PR5 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.